| II-01 Khaled Abduljalil Impact of OATP1B1 Polymorphism on Pravastatin Pharmacokinetics during Pregnancy; Physiologically Based Pharmacokinetic model Prediction Wednesday 15:35-17:00 |
| II-02 Tariq Abdulla Using Simcyp Designer to extend a PBPK-QSP Model of Warfarin to Target Binding Wednesday 15:35-17:00 |
| II-14 Mattia Berton Physiologically based pharmacokinetic modelling to investigate the impact of obesity on the pharmacokinetics of rilpivirine, efavirenz, and etravirine Wednesday 15:35-17:00 |
| II-15 Sara Bettonte Onset and disappearance of induction on CYP3A4 and UGT1A1 substrates using PBPK modelling Wednesday 15:35-17:00 |
| II-21 THAM THI BUI Development of a physiological-based pharmacokinetic model for sacubitril and its metabolite Wednesday 15:35-17:00 |
| II-23 Elisa Calvier PBPK modelling of the DDI between a Drug X and gemfibrozil Wednesday 15:35-17:00 |
| II-27 Marylore Chenel Physiologically based pharmacokinetic (PBPK) modeling of the oral absorption of 5-flucytosine to support further development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis Wednesday 15:35-17:00 |
| II-29 Brian Cicali Long-acting formulation drug-drug interactions: evaluating the importance of timing using a subcutaneous levonorgestrel PBPK example Wednesday 15:35-17:00 |
| II-33 Marina Cuquerella Gilabert Title: Development of a Compartmental Advanced Physiologically based Dissolution, Absorption and Transit (CA-PhysDAT) model in PhysPK Wednesday 15:35-17:00 |
| II-37 Neel Deferm Development of a physiologically-based pharmacokinetic model of enzalutamide, a strong CYP3A4 inducer Wednesday 15:35-17:00 |
| II-38 Cleo Demeester Implementation of Oral Drug Absorption in Older Adults in the Physiologically Based Pharmacokinetic (PBPK) Modelling Platforms Wednesday 15:35-17:00 |
| II-39 Abdallah Derbalah Characterization of the hepatic distribution of oligonucleotide therapeutics using a cross-species biologics PBPK model Wednesday 15:35-17:00 |
| II-41 Ilse Dubbelboer Lactation related milk volume changes: implementation in a PBPK cow model for oxytetracycline Wednesday 15:35-17:00 |
| II-57 Berfin Gülave P-glycoprotein mediated drug-drug interaction at the blood-brain barrier on morphine brain distribution Wednesday 15:35-17:00 |
| II-58 Andrea Guzmán Individualized Tacrolimus dosing in pediatric kidney transplantation: identification of new genomic, proteomic and metabolomic biomarkers and PhysPK® development of PBPK-based predictive models, simulations and applications in different phamacogenomic subpopulations. Wednesday 15:35-17:00 |
| II-61 Sara Carolina Henriques Development of a joint dissolution and pharmacokinetic model of propafenone and its hydroxylated metabolite Wednesday 15:35-17:00 |
| II-65 Manuel Ibarra Enhancing the predictive accuracy of PBPK models for drug concentrations in tissues: accounting for the impact of relative distribution of blood flow Wednesday 15:35-17:00 |
| II-67 Nattapon Jaisupa A physiologically-based pharmacokinetic model for prediction of cannabidiol pediatric dose Wednesday 15:35-17:00 |
| II-68 Masoud Jamei Application of a PBPK Model to Predict the Required Ceftazidime Concentration and Duration in Maternal and Umbilical Plasma Prior to Caesarean Section in Virtual Pregnant Women with Different Renal Function Wednesday 15:35-17:00 |
| III-16 Christos Kaikousidis In Silico Dosimetry Study of Tc99m-Tetrofosmin in Children Using a Novel PBPK Model in Humans Built from SPECT Imaging Data Thursday 10:15-11:45 |
| III-22 Christina Kovar Physiologically Based Pharmacokinetic Modeling of Dasatinib to Describe Enzyme-Mediated and pH-Dependent Drug–Drug Interaction Scenarios Thursday 10:15-11:45 |
| III-24 Katharina Krollik Oral absorption modeling of weakly basic drugs – Combining in vitro and in silico models Thursday 10:15-11:45 |
| III-27 Julia Larsson PK and PBPK modeling approaches to describe the lung and systemic exposure after inhalation of AZD4604 Thursday 10:15-11:45 |
| III-30 Maxime Le Merdy Ocular Exposure Extrapolation Across Multiple Species Using PBPK Modeling and Simulation: Latanoprost Solution Case Study Thursday 10:15-11:45 |
| III-36 Cong Liu Application of translational physiologically based pharmacokinetic (PBPK) model for elucidating the complex disposition of ADCs: a case study with T-DM1 Thursday 10:15-11:45 |
| III-37 Feiyan Liu Unravelling the effects of acute inflammation on pharmacokinetics: a model-based analysis focusing on renal excretion and CYP3A4-mediated metabolism Thursday 10:15-11:45 |
| III-40 Helena Loer Physiologically Based Pharmacokinetic Modeling of Imatinib and Its Main Metabolite for Drug–Drug Interaction Predictions Thursday 10:15-11:45 |
| III-42 Orphélie Lootens Building a physiologically-based pharmacokinetic model for a carcinogenic food contaminant aflatoxin B1 Thursday 10:15-11:45 |
| III-54 Thi Lien Ngo Development of a Physiological-Based Pharmacokinetic Model for Ritonavir: Unraveling its Triphasic Effects as CYP3A Inhibitor, CYP3A Inducer, and Pgp Inhibitor. Thursday 10:15-11:45 |
| III-57 Jessica Ou Development of a physiologically-based pharmacokinetic model to understand and predict the disposition of gallium-68 radiolabeled-dendrimers in vivo Thursday 10:15-11:45 |
| III-59 Sara Peribanez A physiologically-based pharmacokinetic model for V937, a novel oncolytic virus, in mice Thursday 10:15-11:45 |
| III-61 Luna Prieto Garcia An Integrated PBPK-Quantitative Systems Pharmacology Model for Statins to Assess the Variability and Implications of Transporter-Mediated Distribution Thursday 10:15-11:45 |
| III-63 Federico Reali A minimal PBPK mice model to support the preclinical development of drugs against tuberculosis. Thursday 10:15-11:45 |
| III-64 Javier Reig-López Chirality matters: physiologically based pharmacokinetic modelling of ibuprofen enantiomers Thursday 10:15-11:45 |
| III-69 Anuraag Saini Development of mPBPK model to support translation decision-making for novel bispecific therapeutics Thursday 10:15-11:45 |
| III-70 Ayatallah Saleh Unravelling the complex inhibition network of voriconazole and its metabolites using a middle-out PBPK approach Thursday 10:15-11:45 |
| III-81 Erik Sjögren Mechanistic modelling of bioavailability and local immunogenicity after subcutaneous administration within the Open Systems Pharmacology framework Thursday 10:15-11:45 |
| III-90 Cristian Valiante PBPK model-based extrapolation from adults to children to predict furosemide oral solution bioavailability Thursday 10:15-11:45 |
| III-94 Tan Zhang Exploring the impact of obesity on drug clearance using PBPK modelling approaches: influential variables affecting scaling from non-obese to obese subjects for drugs metabolized in the liver Thursday 10:15-11:45 |
